Kim Ra-Yeon, Hong Sung Ok, Jung Jae-Woong, Lee Mu-Hang, Lee Young-Kee, Jee Yu-Jin
Department of Oral and Maxillofacial Surgery, Kyung Hee University Dental Hospital at Gangdong, Kyung Hee University College of Dentistry, Seoul, Korea.
J Korean Assoc Oral Maxillofac Surg. 2024 Oct 31;50(5):285-291. doi: 10.5125/jkaoms.2024.50.5.285.
Medication-related osteonecrosis of the jaw (MRONJ) is a refractory disease that can lead to severe destruction of the jaw. As there is no standard protocol for treating MRONJ, various treatments have been studied. Teriparatide has been used as an adjunct therapy for MRONJ. However, its effectiveness has not been sufficiently demonstrated for use as a standard treatment for MRONJ. This study aimed to demonstrate the efficacy of teriparatide in treating MRONJ by presenting two successfully treated cases. Each patient received teriparatide therapy with surgical intervention. The appropriateness of teriparatide use was evaluated based on the patient's systemic condition, and the administration of teriparatide was supervised by a physician. Complete resolution of the lesion was observed clinically and radiographically in both patients. The first patient underwent implant placement at the lesion site. Due to its anabolic properties and ability to stimulate bone remodeling, teriparatide is an effective adjunctive pharmacological treatment for bone healing before and after surgery with associated beneficial effects on bone and mucosal healing.
药物相关性颌骨坏死（MRONJ）是一种难治性疾病，可导致颌骨严重破坏。由于目前尚无治疗MRONJ的标准方案，因此人们对各种治疗方法进行了研究。特立帕肽已被用作MRONJ的辅助治疗药物。然而，其作为MRONJ标准治疗方法的有效性尚未得到充分证实。本研究旨在通过展示两例成功治疗的病例来证明特立帕肽治疗MRONJ的疗效。每位患者均接受了特立帕肽治疗及手术干预。根据患者的全身状况评估特立帕肽使用的合理性，并由医生监督特立帕肽的给药。两名患者在临床和影像学上均观察到病变完全消退。首例患者在病变部位植入了种植体。由于特立帕肽具有合成代谢特性且能够刺激骨重塑，因此它是一种有效的辅助药物治疗方法，可用于手术前后的骨愈合，并对骨和黏膜愈合具有相关的有益作用。
